STOCKHOLM, Sweden – May 6, 2026
Spago Nanomedical AB (publ) has announced that its ongoing Phase I/IIa Tumorad-01 study evaluating 177Lu-SN201 has achieved a major clinical development milestone after the independent Data Monitoring Committee (DMC) confirmed that the study met a primary endpoint by identifying the maximum tolerated dose (MTD). The committee further recommended enrolling two additional patients at the 15 MBq/kg dose level to support selection of the recommended Phase II dose (RP2D) and complete the Phase I portion of the trial. In addition, the company reported visible tumor uptake in a patient with head and neck cancer, strengthening proof-of-concept for the Tumorad program and supporting the continued advancement of its targeted radionuclide therapy platform for advanced solid tumors.
Visible Tumor Uptake Reinforces Tumorad Mechanism
The Tumorad-01 study is evaluating 177Lu-SN201, a radiopharmaceutical candidate designed to selectively accumulate in tumors and deliver targeted radiation directly to cancer tissue. To date, 15 patients with advanced, metastatic, or treatment-resistant cancers have been treated in the study. The latest patient treated at the highest tested dose level of 20 MBq/kg demonstrated clear tumor uptake in squamous cell carcinoma of the tongue, a difficult-to-treat form of head and neck cancer.
SPECT/CT imaging also showed visible uptake in tumor-affected lymph nodes, providing additional evidence of effective tumor targeting. Earlier in the study, significant uptake had also been observed in a patient with adenoid cystic carcinoma (ACC), another aggressive head and neck cancer subtype. These findings are considered important because they validate the Tumorad platform’s proposed mechanism of action in humans and further strengthen confidence in its ability to selectively deliver therapeutic radiation to malignant tissue.
Safety and Dose Escalation Support Continued Development
Advertisement
Preliminary safety findings from all treated patients indicate that 177Lu-SN201 has demonstrated a consistent and acceptable safety profile across dose levels up to 20 MBq/kg. Based on review of the latest patient data, the DMC concluded that the predefined endpoint for identifying the maximum tolerated dose had been reached. The committee recommended continuation of the study with fractionated treatment of two additional patients at 15 MBq/kg to further evaluate dose optimization and support determination of the RP2D.
Establishing the recommended Phase II dose is a critical objective because it will define the dosing strategy for future efficacy-focused studies. The ability to safely escalate dosing while maintaining tumor-specific uptake represents a significant achievement for the program, especially within the highly competitive field of targeted radiopharmaceutical therapies.
Growing Opportunity in Targeted Radiopharmaceutical Oncology
Spago Nanomedical’s Tumorad platform is part of a rapidly expanding segment of oncology focused on precision radiopharmaceutical therapies, which are increasingly attracting industry attention due to their potential to combine high efficacy with targeted delivery. Unlike traditional chemotherapy, radiopharmaceuticals aim to minimize systemic toxicity by directing radiation specifically toward tumors while sparing healthy tissue.
The repeated observation of visible tumor uptake in aggressive head and neck cancers strengthens the potential commercial and therapeutic value of 177Lu-SN201, particularly for patients with limited treatment alternatives. CEO Mats Hansen stated that defining the RP2D would represent an important milestone for the Tumorad program and place the company in a stronger strategic position as development progresses toward later-stage studies.
Phase II Expansion Plans and Future Outlook
The Tumorad-01 study is a first-in-human Phase I/IIa trial designed to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of 177Lu-SN201 in adult patients with progressive or treatment-resistant advanced solid tumors. With the MTD now identified and additional dose confirmation underway, Spago Nanomedical is preparing for the next stage of development, where the focus will increasingly shift toward generating efficacy data in selected tumor indications.
The combination of favorable safety findings and visible tumor targeting provides a solid foundation for continued clinical expansion. If future studies confirm therapeutic benefit, 177Lu-SN201 could emerge as a promising next-generation radiopharmaceutical therapy within the evolving precision oncology market.
Source: Spago Nanomedical press release
